To the Editor.—
Cocarro et al1 recently reported that pindolol, a serotonin (5-HT-la) antagonist, as well as metergoline, a mixed 5-HT antagonist that also has dopamine agonist properties, inhibited the prolactin (PRL) response to buspirone (0.5 mg/kg administered orally) in two subjects. The inhibitory effect of pindolol was observed at doses of 10 mg and 20 mg in one subject, and at 5 mg and 10 mg in the second subject. In the latter subject, 20 mg of pindolol was reported to increase the PRL response to buspirone. Neither pretreatment had any effect on the ability of buspirone to stimulate the growth hormone, corticotropin, or cortisol. On the basis of this, the authors concluded that the buspirone-induced PRL response is likely to be mediated by a 5-HT-l-like receptor.We were the first to report that buspirone increased PRL secretion in man
Meltzer HY, Hong SL, Nash JF. Effect of Buspirone on Prolactin Secretion Is Not Mediated by 5-HT-1a Receptor Stimulation. Arch Gen Psychiatry. 1992;49(2):163. doi:10.1001/archpsyc.1992.01820020083011
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: